文献速递妇科

子宫内膜癌辅助放疗后序贯化疗与总生存改善相关

Adjuvant radiation followed by chemotherapy is associated with improved overall survival in endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2020-08-15

基于美国国家癌症数据库2004至2015年诊断的I-IVA期子宫内膜癌患者,比较辅助放疗后序贯化疗(RT-CT)、同步放化疗(CCRT)和化疗后序贯放疗(CT-RT)的生存差异。共17,070例患者纳入,RT-CT组5年总生存率为77.3%,高于CCRT组的74.3%和CT-RT组的74.4%(p < .001);倾向性评分匹配后RT-CT组5年总生存率为77.4%,CCRT/CT-RT组为74.2%(p = .001),但差异仅在III期患者中显著。

要点

  • 在I-IVA期子宫内膜癌接受手术、化疗和放疗的患者中,辅助RT-CT相比CT-RT或CCRT与总生存改善相关。
  • RT-CT组5年总生存率为77.3%,CCRT组为74.3%,CT-RT组为74.4%(p < .001)。
  • 倾向性评分匹配后RT-CT组5年总生存率为77.4%,CCRT/CT-RT组为74.2%(p = .001),差异仅在III期患者中显著(73.9% vs 69.7%,p = .002)。

核心结论

  • 研究结果提示,在接受手术、化疗和放疗三联治疗的子宫内膜癌患者中,辅助RT-CT相比CT-RT或CCRT与生存获益相关。
  • 该生存获益可能仅限于III期患者。

研究设计与样本

  • 研究为基于美国国家癌症数据库的队列分析,纳入2004至2015年诊断的I-IVA期子宫内膜癌患者,均接受手术、化疗和放疗。
  • 辅助治疗分为RT-CT(放疗后序贯化疗)、CCRT(同步放化疗,放疗和化疗在7天内开始)和CT-RT(化疗后序贯放疗)三组。
  • 另进行倾向性评分匹配(PSM)队列分析,比较RT-CT与CCRT及CT-RT组。
  • 共纳入17,070例患者,其中RT-CT组12,402例(72.7%),CCRT组2,153例(12.6%),CT-RT组2,515例(14.7%)。
  • 中位随访时间为44.3个月。

主要发现

  • RT-CT组、CCRT组和CT-RT组的5年总生存率分别为77.3%(95% CI 76.4%-78.2%)、74.3%(95% CI 72.0%-76.3%)和74.4%(95% CI 72.5%-76.3%)(p < .001)。
  • 在未匹配队列中按分期分层,辅助RT-CT在I期和III期患者中与总生存改善相关。
  • 在倾向性评分匹配队列中,RT-CT组相比CCRT/CT-RT组的5年总生存率为77.4% vs 74.2%(p = .001)。
  • 在倾向性评分匹配队列中,总生存差异仅在III期患者中显著(RT-CT组73.9% vs CCRT/CT-RT组69.7%,p = .002)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although multimodality therapy has been shown to improve outcomes for patients with high-risk endometrial carcinoma, optimal type and timing of adjuvant therapies is unknown. METHODS: Patients with stage I-IVA endometrial carcinoma diagnosed from 2004 to 2015, and treated with surgery, chemotherapy, and radiation were identified in the National Cancer Database. Adjuvant treatment was categorized as sequential radiation followed by chemotherapy (RT-CT), concurrent chemoradiation (CCRT, RT and CT started within 7 days), or sequential chemotherapy followed by radiation (CT-RT). Analysis for propensity score matched (PSM) cohorts comparing RT-CT to CCRT and CT-RT groups was additionally performed. RESULTS: A total of 17,070 patients were identified, including 12,402 (72.7%) treated with RT-CT, 2,153 (12.6%) with CCRT, and 2,515 (14.7%) with CT-RT. Median follow-up was 44.3 months. Five-year overall-survival (OS) by adjuvant treatment regimen was 77.3% (95% CI 76.4%-78.2%), 74.3% (95% CI 72.0%-76.3%), and 74.4% (95% CI 72.5%-76.3%), respectively (p < .001). When unmatched cohorts were stratified by stage, adjuvant RT-CT was associated with improved OS in stage I and III patients. A similar survival advantage associated with RT-CT was observed in PSM cohorts comparing RT-CT group to CCRT/CT-RT group (5-year OS 77.4% vs 74.2%, p = .001). However, the difference in OS was significant only among stage III patients (RT-CT 73.9% compared to CCRT/CT-RT 69.7%, p =.002). CONCLUSION: Our findings suggest survival benefit with adjuvant RT-CT compared to CT-RT or CCRT in patients undergoing trimodality therapy for endometrial cancer. This survival benefit may be limited to stage III patients.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Sinha S, Lazar A, Lam A, et al. Adjuvant radiation followed by chemotherapy is associated with improved overall survival in endometrial cancer. Gynecol Oncol. 2020. PMID: 32811681. doi:10.1016/j.ygyno.2020.07.098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。